Investment Banking
William Blair investment banking’s biopharma team released its quarterly analysis of the sector—“Quarterly Rx: Q2 2023 U.S. Biopharma Recap”—and drew interest from several industry media outlets, including Fierce Biotech.
“After hitting near rock bottom in the summer of 2022, sentiment is now improving across the sector. The second quarter saw ‘meaningful M&A’—16 transactions totaling $29.1 billion in deal value,” the article cited from the group’s report.
Stay up-to-date with the latest William Blair news and insights
William Blair acted as the exclusive financial advisor to Duomed Group, a portfolio company of G Square Healthcare Private Equity, in connection with the contemplated sale to Palex Medical, a portfolio company of Apax Partners and Fremman Capital.
Read moreAbsent further legislation, The Tax Cuts and Jobs Act will sunset on January 1, 2026, reverting to 2017 levels, adjusted for inflation, or approximately $7M per taxpayer. As a result, wealthy individuals and families will be subject to significantly more federal estate tax in 2026 than they are today.
Read moreUnderstanding the nuances between retirement plans can be challenging. William Blair’s Quick Reference Guide to Retirement Plans compares and contrasts features such as account establishment, account contributions, and accessibility.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
